Download Files:
IPR-803
SKU
HY-111192-10 mg
Category Reference compound
Tags Cancer, Metabolic Enzyme/Protease, Ser/Thr Protease
$250 – $2,048
Products Details
Product Description
– IPR-803 is a potent inhibitor of the uPAR•uPA protein-protein interaction (PPI). IPR-803 binds directly to uPAR with sub-micromolar affinity. IPR-803 displays anti-tumor activity[1].
Web ID
– HY-111192
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C27H23N3O4
References
– [1]Mani T, et al. Small-molecule inhibition of the uPAR•uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis. Bioorg Med Chem. 2013 Apr 1;21(7):2145-55.
CAS Number
– 892243-35-5
Molecular Weight
– 453.49
Compound Purity
– 98.0
SMILES
– O=C(O)C1=CC=CC(NC2=C(C3=C4ON=C3C(N5CCCCCC5)=C2)C(C6=C4C=CC=C6)=O)=C1
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 7.69 mg/mL (ultrasonic)
Target
– Ser/Thr Protease
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.